Inozyme Pharmainc Stock Performance
| INZY Stock | USD 4.40 0.01 0.23% |
The company retains a Market Volatility (i.e., Beta) of 2.9, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Inozyme PharmaInc will likely underperform. Inozyme PharmaInc right now retains a risk of 4.97%. Please check out Inozyme PharmaInc semi variance, rate of daily change, and the relationship between the value at risk and kurtosis , to decide if Inozyme PharmaInc will be following its current trending patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Inozyme PharmaInc has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Inozyme PharmaInc is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return 1.25 | Five Day Return (1.87) | Year To Date Return 2.89 | Ten Year Return (74.60) | All Time Return (74.60) |
1 | Inozyme Pharma, Inc. Shares Purchased by Rock Springs Capital Management LP - MarketBeat | 03/05/2024 |
2 | Acquisition by Subramanian Sanjay of 165000 shares of Inozyme PharmaInc at 5.77 subject to Rule 16b-3 | 03/13/2024 |
3 | Acquisition by Mathers Edward T of 9367 shares of Inozyme PharmaInc at 17.12 subject to Rule 16b-3 | 03/14/2024 |
4 | Inozyme Pharma to Report Topline Data from Ongoing Phase 12 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024 | 03/26/2024 |
5 | Acquisition by Sonsini Peter W. of 187156 shares of Inozyme PharmaInc subject to Rule 16b-3 | 03/27/2024 |
6 | Acquisition by Douglas Treco of 25000 shares of Inozyme PharmaInc subject to Rule 16b-3 | 04/01/2024 |
7 | Disposition of 7523 shares by Douglas Treco of Inozyme PharmaInc at 6.94 subject to Rule 16b-3 | 04/03/2024 |
8 | Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 12 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency | 04/08/2024 |
9 | BofA cuts Inozyme Pharma stock target, maintains buy rating | 04/09/2024 |
10 | Inozyme Pharma, Inc. Short Interest Update - MarketBeat | 04/16/2024 |
| Begin Period Cash Flow | 32.9 M |
Inozyme |
Inozyme PharmaInc Relative Risk vs. Return Landscape
If you would invest 465.00 in Inozyme PharmaInc on January 25, 2024 and sell it today you would lose (25.00) from holding Inozyme PharmaInc or give up 5.38% of portfolio value over 90 days. Inozyme PharmaInc is currently generating 0.0322% in daily expected returns and assumes 4.9658% risk (volatility on return distribution) over the 90 days horizon. In different words, 43% of stocks are less volatile than Inozyme, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Inozyme PharmaInc Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Inozyme PharmaInc's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Inozyme PharmaInc, and traders can use it to determine the average amount a Inozyme PharmaInc's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0065
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | INZY |
Estimated Market Risk
| 4.97 actual daily | 44 56% of assets are more volatile |
Expected Return
| 0.03 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Inozyme PharmaInc is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Inozyme PharmaInc by adding Inozyme PharmaInc to a well-diversified portfolio.
Inozyme PharmaInc Fundamentals Growth
Inozyme Stock prices reflect investors' perceptions of the future prospects and financial health of Inozyme PharmaInc, and Inozyme PharmaInc fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Inozyme Stock performance.
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.28 | ||||
| Current Valuation | 129.8 M | ||||
| Shares Outstanding | 61.77 M | ||||
| Price To Book | 2.26 X | ||||
| EBITDA | (74.35 M) | ||||
| Net Income | (71.17 M) | ||||
| Cash And Equivalents | 151.48 M | ||||
| Cash Per Share | 3.77 X | ||||
| Total Debt | 46.59 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 14.54 X | ||||
| Book Value Per Share | 2.27 X | ||||
| Cash Flow From Operations | (70.67 M) | ||||
| Earnings Per Share | (1.37) X | ||||
| Market Capitalization | 271.8 M | ||||
| Total Asset | 200.85 M | ||||
| Retained Earnings | (285.93 M) | ||||
| Working Capital | 181.56 M | ||||
About Inozyme PharmaInc Performance
To evaluate Inozyme PharmaInc Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Inozyme PharmaInc generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Inozyme Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Inozyme PharmaInc market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Inozyme's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (32.10) | (33.70) | |
| Return On Tangible Assets | (0.35) | (0.37) | |
| Return On Capital Employed | (0.41) | (0.43) | |
| Return On Assets | (0.35) | (0.37) | |
| Return On Equity | (0.51) | (0.48) |
Things to note about Inozyme PharmaInc performance evaluation
Checking the ongoing alerts about Inozyme PharmaInc for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Inozyme PharmaInc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Inozyme PharmaInc had very high historical volatility over the last 90 days | |
| Inozyme PharmaInc has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (71.17 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Inozyme PharmaInc currently holds about 151.48 M in cash with (70.67 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.77. | |
| Inozyme PharmaInc has a poor financial position based on the latest SEC disclosures | |
| Over 93.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Inozyme Pharma, Inc. Short Interest Update - MarketBeat |
- Analyzing Inozyme PharmaInc's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Inozyme PharmaInc's stock is overvalued or undervalued compared to its peers.
- Examining Inozyme PharmaInc's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Inozyme PharmaInc's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Inozyme PharmaInc's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Inozyme PharmaInc's stock. These opinions can provide insight into Inozyme PharmaInc's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inozyme PharmaInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Inozyme Stock please use our How to Invest in Inozyme PharmaInc guide.Note that the Inozyme PharmaInc information on this page should be used as a complementary analysis to other Inozyme PharmaInc's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Complementary Tools for Inozyme Stock analysis
When running Inozyme PharmaInc's price analysis, check to measure Inozyme PharmaInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme PharmaInc is operating at the current time. Most of Inozyme PharmaInc's value examination focuses on studying past and present price action to predict the probability of Inozyme PharmaInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme PharmaInc's price. Additionally, you may evaluate how the addition of Inozyme PharmaInc to your portfolios can decrease your overall portfolio volatility.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |
Is Inozyme PharmaInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inozyme PharmaInc. If investors know Inozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inozyme PharmaInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.37) | Return On Assets (0.28) | Return On Equity (0.55) |
The market value of Inozyme PharmaInc is measured differently than its book value, which is the value of Inozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Inozyme PharmaInc's value that differs from its market value or its book value, called intrinsic value, which is Inozyme PharmaInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inozyme PharmaInc's market value can be influenced by many factors that don't directly affect Inozyme PharmaInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inozyme PharmaInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Inozyme PharmaInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inozyme PharmaInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.